In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
A Small Biotech Takes On Some Big Clinical Trial Challenges
Explore how a small biotech takes on some big clinical trial challenges in Clinical Leader's recent article.
-
Moving Beyond a Buzzword: How Small- to Mid-sized Biotechs Can Adopt Patient Centricity in Oncology Trials
A BioCentury article authored by ICON experts Lucy Clossick Thomson, Senior Director of Oncology Project Management & Susan Campbell, Director of Patient Recruitment, discussing how even small steps toward patient engagement can improve cancer trial recruitment and reduce costs.
-
America's Best Employers for Women
Read about ICON's recent recognition as a top employer for women in Forbes' 2019 List of America’s Best Employers for Women.
-
10 Professionals Predict the Future of Clinical Trials
Discover what the future of clinical trials holds, according to ICON'S Senior Director of Business Development, Sarah Ikard, MBA as recorded by Xtalks in their interview with her at the recent DIA 2019 conference.
-
The long journey towards patient centricity
ICON’s Catherine Acquadro and Benoit Arnould discuss the evolution of patient reported outcomes over the last 30 years in this article on Patient Centricity from the July/August 2019 issue of Pharmafocus.
-
Adoptive Cell Transfer (ACT) Clinical Trials: The Long Road
ICON’s Martin Lachs and Brandon Fletcher provide expert commentary on Adoptive Cell Transfer (ACT) clinical trials in this July 2019 DDN News article.
-
Leveraging Novel Therapeutics & Diagnostic Assays
A European Biopharmaceutical Review article featuring expert insights from ICON company MolecularMD's Marissa Pearce on Leveraging Novel Therapeutics & Diagnostic Assays, presenting her argument that, although immunotherapy is nothing new, it has much untapped potential yet to be explored.
This article has been taken from EBR - Summer 2019, Pages. 78-84. Samedan Ltd.
-
Technology the Key for Improving Trial Efficiencies & Retention
Past reliance on paper records made for a cumbersome, time-consuming process by making data management highly complex. However, many of the biggest issues remain — in particular, recruitment and retention of patients. Most pharmaceutical companies and contract research organisations have adopted technology solutions, including electronic data capture solutions and clinical trial management systems to increase efficiencies, reduce costs, and improve the patient experience. These solutions have been instrumental in improving clinical trial processes. Read this PharmaVOICE article to learn how the use of technology has become ubiquitous in clinical trials as the industry looks to streamline and improve processes.
-
Oncology & ASCO 2019: Moving from Autologous to Allogeneic ACT Paradigms
We have come so far in a relatively short time with Adoptive Cellular Transfer (ACT). ACT approaches have the possibilities of therapies with reduced safety concerns, a higher therapeutic index, as well as breadth of targets including solid tumours. Learn more in our recent Pharmaphorum article.
-
Increasing Predictability in Patient Recruitment
In this recent PharmaVOICE article, ICON expert E.B. McLindon explores the increasing complexity of protocol design, emphasizing the importance of assessing the burden on both the patient and site when evaluating the potential impact on patient recruitment.
